Drug intelligence / Profile preview

MK-6183

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

MK-6183 is a small molecule drug initially developed by Cubist Pharmaceuticals. It has been investigated primarily for its pharmacokinetics and safety profile in individuals with varying degrees of renal impairment, including those with chronic kidney failure and end-stage renal disease requiring hemodialysis. The drug's mechanism of action and molecular target have not been publicly disclosed. Its primary therapeutic area is urogenital diseases, specifically chronic kidney failure. Clinical development appears to have reached Phase 1 as of the last available updates[1][7].

Targets

Neuraminidase

Beyond the preview

Go deeper on MK-6183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-6183.

Explore the full profile